世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

遺伝子治療市場:ベクタータイプ別(ウイルスベクター、非ウイルスベクター)、遺伝子タイプ別(抗原、サイトカイン、腫瘍抑制剤、自殺、欠乏、増殖因子、受容体、その他)、用途別(腫瘍疾患、奇病、心血管疾患、神経疾患、感染症、その他疾患) - 世界の機会分析と産業予測 2017-2023年

Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 

出版社 出版年月電子版価格 ページ数
Allied Market Research
アライドマーケットリサーチ
2018年2月US$5,370
シングルユーザライセンス
232

サマリー

この調査レポートは遺伝子治療市場を分析・予測したAllied Market Researchの市場調査報告書です。

Description

The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Vector Type

Viral vector
Retroviruses
Lentiviruses
Adenoviruses
Adeno Associated Virus
Herpes Simplex Virus
Poxvirus
Vaccinia Virus
Others
Non-viral vector
Naked/Plasmid Vectors
Gene Gun
Electroporation
Lipofection
Others

By Gene Type

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others

By Application

Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious disease
Other Diseases

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Republic of South Africa
Rest of LAMEA

KEY PLAYERS PROFILED

Novartis
Kite Pharma, Inc.
GlaxoSmithKline PLC
Spark Therapeutics Inc.
Bluebird bio Inc.
Genethon
Transgene SA
Applied Genetic Technologies Corporation
Oxford BioMedica
NewLink Genetics Corp.

The other players of the gene therapy market include (companies not profiled in the report):

Amgen
Epeius Biotechnologies
Abeona Therapeutics
Sanofi
UniQure
Juno Therapeutics
Adaptimmune
Celgene
Advantagene



目次

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Top winning strategies, by year, 2015-2017*
3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
3.2.2.3. Top winning strategies, by company, 2015-2017*

3.3. Top player positioning, 2016
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High investment for R&D activities pertaining to gene therapy
3.5.1.2. Increase in prevalence of cancer
3.5.1.3. Growth in awareness regarding gene therapy

3.5.2. Restraints

3.5.2.1. High cost associated with gene therapies
3.5.2.2. Unwanted immune responses

3.5.3. Opportunity

3.5.3.1. Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Viral vectors

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market Analysis by country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-associated virus
4.2.9. Herpes simplex virus
4.2.10. Poxvirus
4.2.11. Vaccinia virus
4.2.12. Others

4.3. Nonviral techniques

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market Analysis by country
4.3.5. Naked plasmid vector
4.3.6. Gene gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Antigen

5.2.1. Market size and forecast
5.2.2. Market size and forecast by country

5.3. Cytokine

5.3.1. Market size and forecast
5.3.2. Market Analysis, by country

5.4. Tumor suppressor

5.4.1. Market size and forecast
5.4.2. Market Analysis, by country

5.5. Suicide

5.5.1. Market size and forecast
5.5.2. Market Analysis, by country

5.6. Deficiency

5.6.1. Market size and forecast
5.6.2. Market Analysis, by country

5.7. Growth factors

5.7.1. Market size and forecast
5.7.2. Market Analysis, by country

5.8. Receptors

5.8.1. Market size and forecast
5.8.2. Market Analysis, by country

5.9. Others

5.9.1. Market size and forecast
5.9.2. Market Analysis, by country

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Oncological disorders

6.2.1. Market size and forecast
6.2.2. Market Analysis, by country

6.3. Rare diseases

6.3.1. Market size and forecast
6.3.2. Market Analysis, by country

6.4. Cardiovascular diseases

6.4.1. Market size and forecast
6.4.2. Market Analysis, by country

6.5. Neurological disorders

6.5.1. Market size and forecast
6.5.2. Market Analysis, by country

6.6. Infectious diseases

6.6.1. Market size and forecast
6.6.2. Market Analysis, by country

6.7. Other diseases

6.7.1. Market size and forecast
6.7.2. Market Analysis, by country

CHAPTER 7: GENE THERAPY MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by country
7.2.4. Market size and forecast, by vector type
7.2.5. Market size and forecast, by gene type
7.2.6. Market size and forecast, by application

7.2.6.1. U.S. market size and forecast, by vector type
7.2.6.2. U.S. market size and forecast, by gene type
7.2.6.3. U.S. market size and forecast, by application
7.2.6.4. Canada market size and forecast, by vector type
7.2.6.5. Canada market size and forecast, by gene type
7.2.6.6. Canada market size and forecast, by application
7.2.6.7. Mexico market size and forecast, by vector type
7.2.6.8. Mexico market size and forecast, by gene type
7.2.6.9. Mexico market size and forecast, by application

7.3. Europe

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by country
7.3.4. Market size and forecast, by vector type
7.3.5. Market size and forecast, by gene type
7.3.6. Market size and forecast, by application

7.3.6.1. Germany market size and forecast, by vector type
7.3.6.2. Germany market size and forecast, by gene type
7.3.6.3. Germany market size and forecast, by application
7.3.6.4. France market size and forecast, by vector type
7.3.6.5. France market size and forecast, by gene type
7.3.6.6. France market size and forecast, by application
7.3.6.7. UK market size and forecast, by vector type
7.3.6.8. UK market size and forecast, by gene type
7.3.6.9. UK market size and forecast, by application
7.3.6.10. Italy market size and forecast, by vector type
7.3.6.11. Italy market size and forecast, by gene type
7.3.6.12. Italy market size and forecast, by application
7.3.6.13. Spain market size and forecast, by vector type
7.3.6.14. Spain market size and forecast, by gene type
7.3.6.15. Spain market size and forecast, by application
7.3.6.16. Rest of Europe market size and forecast, by vector type
7.3.6.17. Rest of Europe market size and forecast, by gene type
7.3.6.18. Rest of Europe market size and forecast, by application

7.4. Asia-Pacific

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by country
7.4.4. Market size and forecast, by vector type
7.4.5. Market size and forecast, by gene type
7.4.6. Market size and forecast, by application

7.4.6.1. Japan market size and forecast, by vector type
7.4.6.2. Japan market size and forecast, by gene type
7.4.6.3. Japan market size and forecast, by application
7.4.6.4. China market size and forecast, by vector type
7.4.6.5. China market size and forecast, by gene type
7.4.6.6. China market size and forecast, by application
7.4.6.7. India market size and forecast, by vector type
7.4.6.8. India market size and forecast, by gene type
7.4.6.9. India market size and forecast, by application
7.4.6.10. South Korea market size and forecast, by vector type
7.4.6.11. South Korea market size and forecast, by gene type
7.4.6.12. South Korea market size and forecast, by application
7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by country
7.5.4. Market size and forecast, by vector type
7.5.5. Market size and forecast, by gene type
7.5.6. Market size and forecast, by application

7.5.6.1. Brazil market size and forecast, by vector type
7.5.6.2. Brazil market size and forecast, by gene type
7.5.6.3. Brazil market size and forecast, by application
7.5.6.4. South Africa market size and forecast, by vector type
7.5.6.5. South Africa market size and forecast, by gene type
7.5.6.6. South Africa market size and forecast, by application
7.5.6.7. Rest of LAMEA market size and forecast, by vector type
7.5.6.8. Rest of LAMEA market size and forecast, by gene type
7.5.6.9. Rest of LAMEA market size and forecast, by application

CHAPTER 8: COMPANY PROFILE

8.1. Adaptimmune Therapeutics Plc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Biocancell Ltd.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio

8.3. Bluebird Bio, Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. Celgene Corporation

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. Gilead Sciences, Inc.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Glaxosmithkline Plc

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Merck & Co., Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Oncogenex Pharmaceuticals, Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. Spark Therapeutics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る